Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photosensitivity potential of bevurogant in healthy volunteers
NCT04147260Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevurogant in plaque psoriasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Photosensitivity Index at 24 Hours Under Condition 1 (Full Range UVB/UVA) and Photosensitivity Index at 24 Hours Under Condition 2 (UVA Only). Started Nov 2019; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04147260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147260.